Pfizer Inc. (PFE)
Why Pfizer Stock Still Looks Deeply Undervalued In 2026
Marty Makary resigned from his position as FDA Commissioner on May 12, in my view, in part because of his inconsistent policy approach. The FDA leadership shake-up continues to this day, but as I'll explain below, this period of uncertainty isn't creating pressure on Big Pharma players, including Pfizer. By the way, Pfizer is still my favorite in the oncology drugs market, trading at a non-GAAP P/E ratio of 8.6x and a high 6.8% dividend yield.
Let's Talk About Your Big “But”
The 1985 classic Pee Wee's Big Adventure is one of my favorite movies. In it, there's a scene where Pee Wee and Simone sit inside the Cabazon dinosaurs as she talks about her dream of going to Paris.
PFE Stock Declines Post Q1 Beat: Book Profits or Stay Invested?
Pfizer stock slipped after Q1 results despite an earnings beat as investors weighed falling COVID sales and looming patent expirations.
Pfizer's Turnaround Is Taking Shape
Pfizer generated $14.5 billion in Q1 revenue, rising 5.7% YoY and beating estimates by $649 million. Acquired products delivered $3.1 billion in Q1 revenue with 22% operational growth, supporting Pfizer's patent cliff transition strategy. Vyndamax exclusivity extension into FY31 reduces Pfizer's projected revenue exposure from $17 billion to approximately $14-$15 billion.
The Zacks Analyst Blog Meta, Pfizer, Salesforce and Smith-Midland
Meta ramps AI infrastructure spending as upgraded recommendations and advertiser tools boost engagement and ad efficiency.
Can Pfizer Achieve High Single-Digit Revenue CAGR From 2029?
PFE targets high single-digit revenue CAGR from 2029 as new launches, acquisitions and pipeline growth may offset LOE headwinds.
Pfizer: Don't Pass On This Dirt-Cheap Buying Opportunity
Pfizer remains materially undervalued, trading at a 9.1x forward earnings multiple and offering a compelling 6.7% dividend yield. LOE headwinds are moderating, with management now expecting $14–15 billion in losses, below prior peak estimates, easing long-term revenue concerns. Execution on recently launched and acquired products is strong, with 22% operational growth and a robust pipeline, particularly in oncology and weight loss.
Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug
Rigel Pharmaceuticals said on Tuesday it has struck a global licensing deal for Arvinas and Pfizer's recently approved breast cancer drug, marking Rigel's fourth commercial product on the market.
Is Most-Watched Stock Pfizer Inc. (PFE) Worth Betting on Now?
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
Pfizer vs Eli Lilly: Different Bets on Pharma M&A
Pfizer (NYSE: PFE | PFE Price Prediction) and Eli Lilly (NYSE: LLY) recently reported quarterly results that read like two scripts from opposite ends of pharma.
Pfizer Beats on Q1 Earnings, New & Acquired Drugs Drive Sales Growth
Pfizer beats Q1 estimates as new launches and acquired drugs lift sales, offsetting COVID declines, while the drugmaker reaffirms its 2026 outlook.
Pfizer beats Q1 revenue and profit estimates, reaffirms 2026 guidance
Pfizer Inc (NYSE:PFE, XETRA:PFE) reported first-quarter 2026 revenue and adjusted profit above Wall Street expectations on Tuesday, driven by strong growth in its launched and acquired products, as the drugmaker reaffirmed its full-year financial outlook. The pharmaceutical giant posted revenue of $14.5 billion for the quarter ended March 31, up 5% from a year earlier and ahead of analyst estimates of $13.84 billion.
